BIOCYTOGEN-B (02315) rose more than 12% in Hong Kong trading. At the time of writing, the stock was up 11.99% to HK$60.25, with a turnover of HK$78.0872 million. The surge follows the company's announcement of its 2025 annual results. Revenue reached RMB 1.379 billion, a year-on-year increase of 40.63%. Net profit attributable to owners of the parent company was RMB 173 million, surging 416.37% compared to the previous year. After adjusting for non-recurring items, net profit was RMB 116 million, up 405.39% year-on-year. Following its first profitable year in 2024, the company's profits experienced explosive growth in 2025. The gross profit margin remained stable at 75.83%, while operating cash flow reached RMB 370 million. Enhanced scale effects have continued to drive improvements in profitability. A key highlight is the significant success of BIOCYTOGEN-B's global expansion strategy. Overseas revenue accounted for nearly 70% of total revenue in 2025, with its service network covering the United States, Europe, and the Asia-Pacific markets. The company has achieved a "reverse globalization" model, gaining recognition from top global pharmaceutical firms through its technological leadership. It has established a local operating subsidiary in the U.S. and regional companies in Europe and Asia-Pacific to directly serve global client needs. This has created a localized service capability not yet seen among domestic peers, advancing the company's position as a "global hub for novel drug discovery."